Navigation Links
Onyx Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
Date:4/24/2008

EMERYVILLE, Calif., April 24 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at the Morgan Stanley Global Healthcare Unplugged Conference on Thursday, May 1, at 8:00 a.m. Eastern Time. Interested parties may access a live web cast of the presentation on our website at:

http://www.onyx-pharm.com/wt/page/event_calendar

It is recommended that listeners log on 15 minutes early in order to register and download any necessary software. For those unable to participate during the live webcast, a recorded replay of the presentation will be available within 24 hours of the completion of the presentation through June 1, 2008.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer by changing the way cancer is treated(TM). The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar(R), a small molecule drug. Nexavar is currently approved for the treatment of advanced kidney cancer and liver cancer. Additionally, Nexavar is being investigated in several ongoing trials in non-small cell lung cancer, melanoma, breast cancer, and other cancers. For more information about Onyx, visit the company's website at http://www.onyx-pharm.com.

Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer Pharmaceuticals Corporation.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Antipodean Pharmaceuticals Announces Results of Phase 2 Study of Lead Compound MitoQ(R)
2. Jazz Pharmaceuticals to Present at Morgan Stanley Conference
3. Aida Pharmaceuticals, Inc. Announces Availability of Downloadable Corporate Synopsis on its Website
4. ISTA Pharmaceuticals Announces Conference Call and Webcast of First Quarter 2008 Financial Results
5. Law Offices of Howard G. Smith Announces 21 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Vertex Pharmaceuticals Inc.
6. Amylin Pharmaceuticals Reports First Quarter Financial Results
7. Ferring Pharmaceuticals EUFLEXXA(TM) to Serve as Sponsor for Sprint Force America Masters Track Club
8. Access Pharmaceuticals Announces New Data on Angiolix(R)
9. Lotus Pharmaceuticals, Inc. Announces Fourth Quarter and Fiscal Year 2007 Results
10. Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2007 Results
11. Sunesis Pharmaceuticals Presents Nonclinical Data on SNS-595 at the Annual Meeting of the American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... and London UK (PRWEB) , ... June 27, 2017 , ... ... to a clinical study is whether they can trust the sponsor to pay them ... is vital that sponsors and CROs establish payment strategies that encourage sites to work ...
(Date:6/27/2017)... ... June 27, 2017 , ... From June 20-22, ... event was held in Syracuse, New York, where EarQ is headquartered. , Together, ... how to connect with today’s savvy consumer, and the latest in hearing technology. ...
(Date:6/27/2017)... ... June 27, 2017 , ... ... of Atmosera Managed Azure Services . The trusted, transparent, and secure solution ... the company’s growing customer base. Atmosera’s next generation services include integrated capabilities for ...
(Date:6/27/2017)... CA (PRWEB) , ... June 27, 2017 , ... ... orthodontic treatments . Orthodontics is a dental specialty that focuses on treating alignment ... Benefits include improved aesthetics and function. , North Hollywood dentist , ...
(Date:6/26/2017)... ... June 26, 2017 , ... ... & Sexual Medicine Specialists, in collaboration with the Fertility Center of California, is ... care: PESA (percutaneous epidydimal sperm aspiration) and TESA (percutaneous testicular sperm extraction). These ...
Breaking Medicine News(10 mins):
(Date:6/16/2017)...  Exactly 50 years ago today, the Monterey Pop Festival ... as the San Francisco "Summer of Love."  To celebrate the ... innovations in strategic market research portals that it will begin ... of Northern Light,s "Summer of Love (For Our Customers)."  ... ...
(Date:6/14/2017)...  In 2016, Embodied Labs took top ... and came away with $25,000 in seed-fund investment. Embodied ... as "entering the life of another" and by the ... to medical professionals in an entirely new dimension." Building ... finalist for the Department of Education,s EdSimChallenge, where they ...
(Date:6/11/2017)... , June 10, 2017  Eli Lilly and Company (NYSE: ... three Phase 3 studies of galcanezumab, an investigational treatment ... late-breaking data on several key secondary endpoints for galcanezumab ... from these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be ... scientific meeting in Boston . ...
Breaking Medicine Technology: